Six Medical 鶹ýӰ With the Highest Hourly Wages Plastic and orthopedic surgery top the list Jan 27, 2022
Psoriasis Patients, Docs Want to Do More to Prevent Heart Problems Despite well-known cardiovascular risks, most patients currently undertreated Jan 19, 2022
FDA OKs Two Oral JAK Inhibitors for Refractory Atopic Dermatitis Once-daily abrocitinib and upadacitinib join topical ruxolitinib in expanding AD market Jan 18, 2022
Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
IL-13 Inhibitor Approved for Adults With Atopic Dermatitis Significantly greater lesion clearance with tralokinumab in placebo-controlled studies Dec 28, 2021
Doc Fired After Standing Up to Private Equity; RFK Jr.'s Anti-Vax Machine This past week in healthcare investigations Dec 22, 2021
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
Think TikTok Is Smarter Than Me? Then I'm Not the Right Doctor for You Modern times have fundamentally altered the landscape of healthcare Nov 30, 2021
Signs of Relief From 'Therapeutic Drought' in Atopic Dermatitis Encouraging results from pipeline agents targeting Th2-specific inflammation Nov 09, 2021
Could This Biologic Drug Work in Patients Lacking Its Target? Bizarre finding with omalizumab Nov 07, 2021
Dramatic Responses in Cutaneous Sarcoidosis With JAK Inhibitor More than 80% reduction in disease activity in case series of tofacitinib treatment Nov 07, 2021
Substantial Improvement in Vitiligo With Topical JAK Inhibitor About 30% of patients had 75% clearance after 6 months, half had 50% clearance Nov 06, 2021
Early Success With New Target in Atopic Dermatitis Inhibition of Th2-related inflammation leads to rapid improvement in disease activity Nov 05, 2021
Topical PDE4 Inhibitor Impresses in Trial of Seborrheic Dermatitis Rapid, persistent improvement in body surface area, itch, other symptoms with roflumilast Nov 04, 2021
How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
Botox Doc's License Suspended Over Breast, Penis Enhancement Harms One patient allegedly required two surgeries to fix penile enhancement gone wrong Oct 21, 2021
FDA to Make Isotretinoin Prescribing Gender Neutral Revision to risk management program dissociates gender from reproductive categories Oct 18, 2021
Is Private Equity a Dangerous Employer? Firms' investments in healthcare continue to expand, at what cost? Oct 14, 2021
Case: VEGFR Inhibition in Merkel Cell Carcinoma Patient Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
FDA Warns on Needle-Free Injection Devices for Facial Fillers Serious injuries and "irreversible" harm to skin, lips, and eyes reported with unapproved devices Oct 08, 2021
FDA Issues Orders Clarifying Rules for Marketing Sunscreens But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
FDA Approves First Topical JAK Inhibitor for Atopic Dermatitis Significant skin clearance, reduced itch in majority of patients treated with ruxolitinib cream Sep 22, 2021
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor? Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
Oral Drug Active in Teens With Atopic Dermatitis Significant improvement at 12 weeks in 42-46% by one index, 68-72% by another Aug 24, 2021
Dual IL-17 Inhibitor Achieves Deep Responses in Hidradenitis Suppurativa Bimekizumab outclasses placebo, compares favorably with adalimumab Aug 20, 2021
Adalimumab Adds to Surgery Benefits for Hidradenitis Suppurativa Significantly higher response rates before and after surgery with biologic agent Aug 18, 2021
Third Dose a Charm in Israel? Door-to-Door 'Goons'; Cervids Catch COVID, Too! A daily roundup of news on COVID-19 and the rest of medicine Jul 30, 2021
Acne Takes a Toll on Women's Mental Health, Quality of Life Almost half reported self-consciousness, adverse effects on professional, social, personal lives Jul 28, 2021
Rates of Serious Infection Differ Among Psoriasis Therapies Low overall rate, small differences versus etanercept reference, large French study showed Jul 22, 2021
FDA Approves IVIG for Dermatomyositis Octagam 10% lands indication for adults following results of ProDERM trial Jul 20, 2021
Shingles Risk Slashed in IBD Patients After Vaccine Study found certain medications also showed lower incidence rates Jul 20, 2021
Skin Rash Should Be a Huge Red Flag for LVAD Recipients, Group Says New phenomenon suggests perils of not performing biopsy in time Jul 07, 2021
COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxed A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
Target TNF or IL-12/23 in Psoriatic Arthritis? Both TNF inhibitors and ustekinumab were effective in real-world use Jun 30, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
